NASDAQ:NARI

Inari Medical (NARI) Stock Price, News & Analysis

$41.82
-0.99 (-2.31%)
(As of 05/8/2024 ET)
Today's Range
$41.48
$42.70
50-Day Range
$37.11
$58.26
52-Week Range
$36.73
$71.85
Volume
704,847 shs
Average Volume
1.17 million shs
Market Capitalization
$2.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.71

Inari Medical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
57.1% Upside
$65.71 Price Target
Short Interest
Healthy
7.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Inari Medical in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$3.57 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.41) to $0.20 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.49 out of 5 stars

Medical Sector

272nd out of 905 stocks

Surgical & Medical Instruments Industry

38th out of 95 stocks

NARI stock logo

About Inari Medical Stock (NASDAQ:NARI)

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

NARI Stock Price History

NARI Stock News Headlines

Could this Tiny Biotech End Disease Forever?
Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.
Could this Tiny Biotech End Disease Forever?
Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.
Inari Medical (NASDAQ:NARI) Shares Gap Up to $37.34
Inari Medical (NASDAQ:NARI) PT Lowered to $84.00
Q1 2024 Inari Medical Inc Earnings Call
See More Headlines
Receive NARI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inari Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
5/08/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NARI
Fax
N/A
Employees
1,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$65.71
High Stock Price Target
$84.00
Low Stock Price Target
$50.00
Potential Upside/Downside
+57.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-1,640,000.00
Pretax Margin
-2.04%

Debt

Sales & Book Value

Annual Sales
$493.63 million
Cash Flow
$0.09 per share
Book Value
$8.07 per share

Miscellaneous

Free Float
51,975,000
Market Cap
$2.43 billion
Optionable
Optionable
Beta
0.93
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives


NARI Stock Analysis - Frequently Asked Questions

Should I buy or sell Inari Medical stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NARI shares.
View NARI analyst ratings
or view top-rated stocks.

What is Inari Medical's stock price target for 2024?

7 Wall Street analysts have issued twelve-month price targets for Inari Medical's stock. Their NARI share price targets range from $50.00 to $84.00. On average, they anticipate the company's share price to reach $65.71 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price.
View analysts price targets for NARI
or view top-rated stocks among Wall Street analysts.

How have NARI shares performed in 2024?

Inari Medical's stock was trading at $64.92 at the beginning of the year. Since then, NARI shares have decreased by 35.6% and is now trading at $41.82.
View the best growth stocks for 2024 here
.

When is Inari Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our NARI earnings forecast
.

How were Inari Medical's earnings last quarter?

Inari Medical, Inc. (NASDAQ:NARI) issued its earnings results on Wednesday, February, 28th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.01 by $0.09. The business had revenue of $132.10 million for the quarter, compared to the consensus estimate of $131.82 million. Inari Medical had a negative net margin of 4.54% and a negative trailing twelve-month return on equity of 1.65%. The firm's quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.11) EPS.

What guidance has Inari Medical issued on next quarter's earnings?

Inari Medical issued an update on its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $592.5 million-$602.5 million, compared to the consensus revenue estimate of $588.4 million.

What other stocks do shareholders of Inari Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY).

When did Inari Medical IPO?

Inari Medical (NARI) raised $110 million in an initial public offering on Friday, May 22nd 2020. The company issued 7,300,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

Who are Inari Medical's major shareholders?

Inari Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (0.59%), Principal Financial Group Inc. (0.53%), Motley Fool Wealth Management LLC (0.25%), Swiss National Bank (0.18%), Motley Fool Asset Management LLC (0.11%) and New York State Teachers Retirement System (0.10%). Insiders that own company stock include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Mitch C Hill, Mitch C Hill, Stanley Tang, Thomas Tu and William Hoffman.
View institutional ownership trends
.

How do I buy shares of Inari Medical?

Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NARI) was last updated on 5/8/2024 by MarketBeat.com Staff

From Our Partners